Terms: = Thyroid cancer AND NCOR1, hCIT529I10, 9611, ENSG00000141027, N-CoR, MGC104216, TRAC1, O75376, hN-CoR, KIAA1047
32 results:
1. Inhibition of kras-derived exosomes downregulates immunosuppressive BACH2/GATA-3 expression via RIP-3 dependent necroptosis and miR-146/miR-210 modulation.
Petanidis S; Domvri K; Porpodis K; Anestakis D; Freitag L; Hohenforst-Schmidt W; Tsavlis D; Zarogoulidis K
Biomed Pharmacother; 2020 Feb; 122():109461. PubMed ID: 31918262
[TBL] [Abstract] [Full Text] [Related]
2. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract] [Full Text] [Related]
3. Whole-Exome Sequencing Identifies Two Discrete Druggable Signaling Pathways in Follicular thyroid cancer.
Erinjeri NJ; Nicolson NG; Deyholos C; Korah R; Carling T
J Am Coll Surg; 2018 Jun; 226(6):950-959.e5. PubMed ID: 29571661
[TBL] [Abstract] [Full Text] [Related]
4. Gene Signature Associated with Upregulation of the Wnt/β-Catenin Signaling Pathway Predicts Tumor Response to Transarterial Embolization.
Ziv E; Yarmohammadi H; Boas FE; Petre EN; Brown KT; Solomon SB; Solit D; Reidy D; Erinjeri JP
J Vasc Interv Radiol; 2017 Mar; 28(3):349-355.e1. PubMed ID: 28126478
[TBL] [Abstract] [Full Text] [Related]
5. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.
Xing M; Alzahrani AS; Carson KA; Viola D; Elisei R; Bendlova B; Yip L; Mian C; Vianello F; Tuttle RM; Robenshtok E; Fagin JA; Puxeddu E; Fugazzola L; Czarniecka A; Jarzab B; O'Neill CJ; Sywak MS; Lam AK; Riesco-Eizaguirre G; Santisteban P; Nakayama H; Tufano RP; Pai SI; Zeiger MA; Westra WH; Clark DP; Clifton-Bligh R; Sidransky D; Ladenson PW; Sykorova V
JAMA; 2013 Apr; 309(14):1493-501. PubMed ID: 23571588
[TBL] [Abstract] [Full Text] [Related]
6. Expression and function of the vitamin D receptor in malignant germ cell tumour of the testis.
Bremmer F; Thelen P; Pottek T; Behnes CL; Radzun HJ; Schweyer S
Anticancer Res; 2012 Jan; 32(1):341-9. PubMed ID: 22213325
[TBL] [Abstract] [Full Text] [Related]
7. Resistance to thyroid hormone is modulated in vivo by the nuclear receptor corepressor (ncor1).
Fozzatti L; Lu C; Kim DW; Park JW; Astapova I; Gavrilova O; Willingham MC; Hollenberg AN; Cheng SY
Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17462-7. PubMed ID: 21987803
[TBL] [Abstract] [Full Text] [Related]
8. Differential recruitment of nuclear coregulators directs the isoform-dependent action of mutant thyroid hormone receptors.
Fozzatti L; Lu C; Kim DW; Cheng SY
Mol Endocrinol; 2011 Jun; 25(6):908-21. PubMed ID: 21474540
[TBL] [Abstract] [Full Text] [Related]
9. ncor1 regulates thyroid hormone receptor isoform-dependent adipogenesis.
Zhu XG; Kim DW; Goodson ML; Privalsky ML; Cheng SY
J Mol Endocrinol; 2011 Jun; 46(3):233-44. PubMed ID: 21389087
[TBL] [Abstract] [Full Text] [Related]
10. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
Trtková K; Pašková L; Matiješčuková N; Kolář Z
Cancer Biomark; 2010; 7(2):79-90. PubMed ID: 21178266
[TBL] [Abstract] [Full Text] [Related]
11. Binding of AR to SMRT/n-cor complex and its co-operation with PSA promoter in prostate cancer cells treated with natural histone deacetylase inhibitor NaB.
Trtkova K; Paskova L; Matijescukova N; Strnad M; Kolar Z
Neoplasma; 2010; 57(5):406-14. PubMed ID: 20568894
[TBL] [Abstract] [Full Text] [Related]
12. Elevated ncor1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesion.
Battaglia S; Maguire O; Thorne JL; Hornung LB; Doig CL; Liu S; Sucheston LE; Bianchi A; Khanim FL; Gommersall LM; Coulter HS; Rakha S; Giddings I; O'Neill LP; Cooper CS; McCabe CJ; Bunce CM; Campbell MJ
Carcinogenesis; 2010 Sep; 31(9):1650-60. PubMed ID: 20466759
[TBL] [Abstract] [Full Text] [Related]
13. Novel orphan nuclear receptors-coregulator interactions controlling anti-cancer drug metabolism.
Gollamudi R; Gupta D; Goel S; Mani S
Curr Drug Metab; 2008 Sep; 9(7):611-3. PubMed ID: 18781912
[TBL] [Abstract] [Full Text] [Related]
14. The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for full estrogen receptor alpha transcriptional activity.
Peterson TJ; Karmakar S; Pace MC; Gao T; Smith CL
Mol Cell Biol; 2007 Sep; 27(17):5933-48. PubMed ID: 17591692
[TBL] [Abstract] [Full Text] [Related]
15. Epigenetic corruption of VDR signalling in malignancy.
Abedin SA; Banwell CM; Colston KW; Carlberg C; Campbell MJ
Anticancer Res; 2006; 26(4A):2557-66. PubMed ID: 16886664
[TBL] [Abstract] [Full Text] [Related]
16. thyroid hormone receptors mutated in liver cancer function as distorted antimorphs.
Chan IH; Privalsky ML
Oncogene; 2006 Jun; 25(25):3576-88. PubMed ID: 16434963
[TBL] [Abstract] [Full Text] [Related]
17. Clinical and molecular features of a TSH-secreting pituitary microadenoma.
Usui T; Izawa S; Sano T; Tagami T; Nagata D; Shimatsu A; Takahashi JA; Naruse M
Pituitary; 2005; 8(2):127-34. PubMed ID: 16379036
[TBL] [Abstract] [Full Text] [Related]
18. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor.
Yoon HG; Wong J
Mol Endocrinol; 2006 May; 20(5):1048-60. PubMed ID: 16373395
[TBL] [Abstract] [Full Text] [Related]
19. Steroid hormone receptors and coregulators in endocrine-resistant and estrogen-independent breast cancer cells.
Sarvilinna N; Eronen H; Miettinen S; Vienonen A; Ylikomi T
Int J Cancer; 2006 Feb; 118(4):832-40. PubMed ID: 16152593
[TBL] [Abstract] [Full Text] [Related]
20. Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in n-cor and SMRT.
Keeton EK; Brown M
Mol Endocrinol; 2005 Jun; 19(6):1543-54. PubMed ID: 15802375
[TBL] [Abstract] [Full Text] [Related]
[Next]
